EUVIMEDEUVIMED entdecken
Kohortenstudie

Autoantibody prevalence and clinical outcomes in Omani chronic kidney disease patients: A retrospective cohort study

Hajar Hamed Alghailani, Issa Al Salmi, Hamed Ali Ahmad AlShahri, Shaima Al Shidi, Michael Mamdouh Soliaman, Fady Elias, Amer Al Amri

World Advances in Renal Medicine · 2026

DOI: 10.25259/warm_6_2026 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift World Advances in Renal Medicine, 2026. Verfasst von Hajar Hamed Alghailani und 6 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The incidence and prevalence of chronic kidney disease (CKD) are rising globally, driven by an increase in non-communicable diseases and autoimmune disorders. While the role of autoimmunity in CKD is recognized, its specific impact on the Omani population is not well understood. This study aimed to determine the prevalence of various autoantibodies in clinically suspected Omani CKD patients and to evaluate their association with disease progression and mortality. Material and Methods: We conducted a retrospective cohort study at a major tertiary hospital in Oman, including 800 CKD patients who attended the adult nephrology outpatient clinic between July 2016 and July 2020. Autoantibody testing was performed based on specific clinical indications. Clinical and laboratory data were collected at the first encounter, with a mean follow-up period of 5.5 years. The primary outcomes were the rate of estimated glomerular filtration rate (eGFR) decline and all-cause mortality.

Results

The study population consisted of 53.4% males, with a mean age of 45.2 years. The prevalence of autoantibodies was 26.7% among tested CKD patients, with a higher prevalence in younger females. The most common autoantibodies were lupus anticoagulant (39.3%), anti-nuclear antibody (ANA) (23.5%), anti-SSA-RO (14.8%), anti-double stranded DNA (13.6%), and anti-Ro52 (10.8%). Multivariate regression analysis revealed a significant association between the presence of autoantibodies, particularly ANA, and a more rapid decline in eGFR (R 2 = 38%). Furthermore, autoantibody positivity was associated with an increased risk of all-cause mortality, even after adjusting for baseline covariates in multivariable Cox regression analysis.

Conclusion

Autoimmune antibodies are highly prevalent in clinically suspected Omani CKD patients and are significantly associated with disease progression and mortality. These findings underscore the importance of targeted screening for autoimmunity in this patient population to facilitate early intervention and improve clinical outcomes. Further research is needed to explore the underlying mechanisms and to develop targeted therapeutic strategies.

Zitieren

APA

Alghailani, H. H., Salmi, I. A., AlShahri, H. A. A., Shidi, S. A., Soliaman, M. M., Elias, F., & Amri, A. A. (2026). Autoantibody prevalence and clinical outcomes in Omani chronic kidney disease patients: A retrospective cohort study. World Advances in Renal Medicine. https://doi.org/10.25259/warm_6_2026

Vancouver

Alghailani HH, Salmi IA, AlShahri HAA, Shidi SA, Soliaman MM, Elias F, et al. Autoantibody prevalence and clinical outcomes in Omani chronic kidney disease patients: A retrospective cohort study. World Advances in Renal Medicine. 2026. doi:10.25259/warm_6_2026

BibTeX
@article{Alghailani2026,
  author = {Alghailani, Hajar Hamed and Salmi, Issa Al and AlShahri, Hamed Ali Ahmad and Shidi, Shaima Al and Soliaman, Michael Mamdouh and Elias, Fady and Amri, Amer Al},
  title = {Autoantibody prevalence and clinical outcomes in Omani chronic kidney disease patients: A retrospective cohort study},
  journal = {World Advances in Renal Medicine},
  year = {2026},
  doi = {10.25259/warm_6_2026}
}
Kostenlos starten →